ACM
IRD

Altium Capital Management’s Opus Genetics IRD Stock Holding History

Altium Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-397,036
Closed -$2.31M – 159
2021
Q1 		$2.31M Sell
397,036
-1,671,494
-81% -$15.5M 0.64% 66
2020
Q4 		$13.4M Buy
+2,068,530
New +$14.3M 5.01% 1

Other funds holding IRD

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
NPF
Norris Perne & French Grand Rapids, Michigan $2.34B AUM 32.04% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Altium Capital Management's IRD Position: Q2 2021 in Review

Altium Capital Management sold out of Opus Genetics (IRD) in Q2 2021, closing a stake of 397,036 shares — an estimated $2.31M sold.

Altium Capital Management first reported a position in IRD in Q4 2020 and held it in 2 quarters. The position peaked at $13.4M in Q4 2020. 36 funds tracked by Wall St. Rank hold IRD as of Q2 2021.

  • Altium Capital Management reported no remaining Opus Genetics position as of Q2 2021 after selling out during the quarter.
  • Altium Capital Management sold 397,036 Opus Genetics shares in Q2 2021, an estimated $2.31M.
  • Altium Capital Management first reported a position in Opus Genetics in Q4 2020 and held it in 2 quarters.
  • Altium Capital Management's Opus Genetics position peaked at $13.4M in Q4 2020.
  • 36 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2021.

Based on Altium Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.